• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Patritumab

CAS No. 1262787-83-6

Patritumab ( —— )

产品货号. M36726 CAS No. 1262787-83-6

Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对 ERBB3 的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用,可有效抑制 EGFR,HER2,HER3,ERK 和 AKT 的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis),也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥3837 有现货
5MG ¥6363 有现货
10MG ¥9932 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Patritumab
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对 ERBB3 的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用,可有效抑制 EGFR,HER2,HER3,ERK 和 AKT 的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis),也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。
  • 产品描述
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
  • 体外实验
    Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.:Western Blot Analysis Cell Line:DiFi-HRG cells Concentration:10 μg/mL Incubation Time:6 hours Result:Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.
  • 体内实验
    Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.Animal Model:Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)Dosage:1 mg/body Administration:Intraperitoneal injection; twice a week for 4 weeks Result:Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
  • 同义词
    ——
  • 通路
    MAPK/ERK Signaling
  • 靶点
    ERK
  • 受体
    ERK | EGFR | HER | Akt
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1262787-83-6
  • 分子量
  • 分子式
    ——
  • 纯度
    >98% (HPLC)
  • 溶解度
    ——
  • SMILES
    ——
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5(23):11847-56. ?
产品手册
关联产品
  • BAY-885

    BAY-885 (BAY885) 是一种高效、选择性 ERK5 (MAPK7) 抑制剂,IC50 为 40 nM。

  • AZ32

    AZ32 是一种口服生物利用型、可穿透血脑屏障的 ATM 抑制剂,对 ATM 酶的 IC50 为 <6.2 nM,对细胞内 ATM 的 IC50 为 0.31 μM。

  • Muramyl dipeptide

    Muramyl 二肽是一种合成的免疫反应肽,由连接到 L-Ala-D-isoGln 短氨基酸链上的 N-乙酰胞壁酸组成。